1、www.pwc.ch/pharmaHow to develop and commercialise digital health solutionsInsights from our digital health leader surveyExecutive summaryAfter years of record investment and a major leap forward in digital healthcare sparked by the COVID-19 crisis,there are now some signs that enthusiasm for digital

2、 health is waning.This can be seen in tighter market conditions and falling adoption of telehealth.However,we believe that pessimism about the overall prospects for digital health would be premature.Behind the hype for telehealth,the pandemic has brought a fundamental change in both the technology i

3、nfrastructure as well as the mindset of healthcare stakeholders.Both of these will enable the formation of true digital health ecosystems that bring value for patients and healthcare professionals and increase the efficiency of care workflows.To play a full part in the development of these ecosystem

4、s,pharma and MedTech leaders face the challenges of developing digital health solutions that meaningfully impact the lives of their users and then finding the right commercial approach that ensures adoption and sustainable business impact.2|How to develop and commercialise digital health solutions 5

5、Strategy recommendationsCompanies need to tackle the unmet needs of patients and go through the rigour of collecting evidenceOur survey records an increased focus on regulated solutions,with 65%of respondents saying they will concentrate on those in the future.In order to move rapidly along that pat

6、h and create the so-lutions that will have the greatest impact,we recommend that com-panies involve regulatory teams at an early stage and take a strategic view of when best to involve the customer in solution development.Reimbursement will become more important,but com-panies should not focus on on